content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

Verastem, Inc. (VSTM)

8.28
-0.10
(-1.19%)
Sep 11, 4:00PM EDT
content_middle

Verastem (VSTM), a biopharmaceutical company, focuses on discovering and developing drugs for the treatment of cancer.

VSTM programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds.

VSTM's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma.

VSTM's duvelisib is in Phase 3 randomized and two-arm trial for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, as well as completed the Phase 2 study for the treatment of patients with refractory indolent non-Hodgkin lymphoma.

VSTM has license agreement with Infinity Pharmaceuticals, Inc.; The Scripps Research Institute; and Pfizer (PFE).

Verastem, Inc. was founded in 2010 and is headquartered in Needham, Massachusetts.

Previous Close: 
5.29
Open: 
5.40
Bid: 
5.38
Ask: 
5.49
1yr Target Price: 
10.00
Day's Range: 
5.19 - 5.51
52wk Range: 
2.77 - 9.14
Volume: 
2301442
Average Daily Volume: 
1441650
Market Capitalization: 
609.34M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
73.59M
content_right

Pages